Warhound: $200M Raised to Engineer Military Canines

Warhound, a stealth startup emerging from obscurity on Thursday, has secured $200 million in funding to develop genetically engineered war dogs for the U.S. military, law enforcement, and emergency response teams. The venture, which values the company at $1.2 billion, is backed by prominent investors including Sequoia, 8VC, Corner Ventures, and In-Q-Tel, a venture firm supported by the CIA and other U.S. intelligence agencies. This significant capital injection marks a pivotal shift in how tactical canines are sourced and prepared for duty.

The financial scale of the operation is designed to address a critical gap in the current supply chain. According to the company’s launch announcement, more than 80% of the U.S. military’s working dogs are currently imported from Europe. Furthermore, fewer than half of these imported canines are deemed fit for service upon arrival. This reliance on foreign sources highlights a diminishing domestic supply, prompting Warhound to propose a technological solution that reduces dependency on overseas breeding programs.

The project is a collaboration between Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril. Lamm and Luckey connected approximately a year ago at a conference, where Luckey expressed a desire for greater innovation in military canine support. Lamm subsequently researched the breeding of working dogs, identifying that many fail training due to inherited issues such as poor eyesight, cancer predisposition, hip dysplasia, or muscle atrophy. Lamm believes that genetic editing can enhance health, longevity, speed, agility, and olfactory capabilities, particularly for bomb detection.

The technical approach involves studying top-performing breeds, specifically the Belgian Malinois and German Shepherd. The team has established a biobank using cell lines from these breeds to edit genes, aiming to create a new type of dog optimized for demanding missions. Anduril will provide the technological overlay, including software and hardware like protection vests and goggles. These devices are designed to improve situational awareness for both the dog and its handler, with sensors potentially feeding data back to operators to enhance coordination and safety.

Colossal Biosciences, known for its de-extinction efforts, holds equity in Warhound and licenses its gene cloning technology to the venture. Viagen, another Colossal-owned entity, will handle the cloning process, leveraging its high success rates to incubate the first batch of dogs. Lamm noted that births are expected early next year, with the animals ideally entering service within two years. The company has briefed various government groups and expects to sell to first responders, the Department of Defense, and police forces, though pricing remains undetermined.

To ensure ethical standards, Warhound is working under the guidance of the American Humane Society to certify its training program. The Society, which describes itself as grounded in science and ethics, stated that it looks forward to working with the company to ensure the animals are treated humanely. Additionally, the program aims to facilitate the retirement of these dogs into the Society’s Military Working Dog Reunification Program, providing homes for them after their service ends. Each dog will be trained and managed by the purchasing agency, ensuring integration into existing operational frameworks.